The presentation videos and slides for speakers’ lectures are made available, provided that they have granted us permission to do so.
Topics
Meeting category
Date(s)
21 Jul 2023 - 22 Jul 2023
Location
Brisbane,
QLD,
Australia
Meeting type
Hybrid Meeting
CME credits
14
International Workshop on HIV & Pediatrics 2023
Related Enduring Materials
Enduring Materials
Day 1 - Friday, 21 July 2023
Session 1: Global Update on Pediatric HIV -
2023 Global Update on the HIV Epidemic in Infants, Children, Adolescents and Women
Elimination of New Paediatric Infections: Where We Are Now and Considerations for the Next Generation of Postnatal Prophylaxis
The Epidemiology of HIV in Pregnant Women, Children, and Adolescents in the Asia-Pacific
Session 2: Pediatric Care and Treatment - Advanced HIV Disease (AHD) in Children and Adolescents -
Glenda E. Gray, MBBCH, FCPaeds (SA), DSc
Optimizing Recognition and Treatment of Advanced HIV Disease in Children and Adolescents
Country Experiences with Pediatric AHD: South Africa
Country Experiences with Pediatric AHD: Philippines
Advances in HIV Vaccines for Prevention and Treatment
South African Medical Research Council (SAMRC), South Africa
Session 3: Comorbidities/Co-Infections -
Robyn Silcock, MBBS (Hons I), BMedSc (Hons I), BA, DCH, MPH, MHM
Treatment of MDR/XDR TB in Children
Prevention of MDR/XDR TB in Children
Cabotegraivr-LA for HIV Prevention in Pregnant Women or Neonates
Clinical Case Presentation 1
Clinical Case Presentation 2
Queensland Children’s Hospital, Australia
5:35 PM
Poster Viewing & Welcome Reception
Poster Walk 1: Adolescents and HIV
Moderator
Dr. Annette Sohn
#60 - Cardiometabolic Risk Profiles of Adolescents living with Perinatally Acquired HIV in South Africa
Lisa Frigati, South Africa
#61 - Change in Size-Adjusted Bone Density Outcomes by HIV Status Among Peripubertal Children in Zimbabwe: A Prospective Cohort Study
Lisha Jeena, United Kingdom
#62 - Cognitive Functioning Using a Mobile-Based Tool in Adolescents and Youth Living With HIV in Kenya
Michelle Bulterys, United States
#63 - High Prevalence and Low Awareness of Chronic Hepatitis in Adolescents Living with HIV in Thailand
Krisanee Pansue, Thailand
Poster Walk 2: Pediatric Care and Treatment
Moderator
Dr. Rachel Vreeman
#31 - Neonatal Outcomes of Children who are HIV Exposed and Uninfected Compared with HIV Unexposed in Western Kenya
Megan McHenry, United States
#87 - Barriers to ART Adherence in Neonates and Infants from the LIFE Study in Mozambique
W. Chris Buck, Mozambique
#88 - Early Virological Response to Dolutegravir in Children and Adolescents Living with HIV in Ugandan UP-ART Cohort Study
Eleanor Namusoke-Magongo, Uganda
#89 - The CHERISH (Children HIV-Exposed Research to Inform Survival and Health) Dynamic Cohort
Heinrich Cupido, South Africa
#32 - Low Levels of Self-Efficacy and Indicators of Depression Predict n-viral Suppression Using the AIDS Clinical Trials Group Adherence Questionnaire Among Women Living With HIV in Kampala, Uganda
Patience Atuhaire, Uganda
Day 2 - Saturday, 22 July 2023
Session 4: Prevention of New Pediatric HIV Infections (and Improving Maternal Health) -
Nadia Sam-Agudu, MD, CTropMed
Challenges in and Strategies for Elimination of Perinatal HIV Transmission in Asia-Pacific: Timor-Leste
Challenges in and Strategies for Elimination of Perinatal HIV Transmission in Asia-Pacific: Papua New Guinea
Debate: Long-Acting Injectable ART Will Solve Adolescent ART Adherence Problems
University of Minnesota / Institute of Human Virology Nigeria, United States / Nigeria
Hepatitis C in children: Epidemiology, Diagnosis, Treatment
Short Oral Poster Presentations
Industry-Supported Symposium
Session 5: Adolescents and Young Adults -
Strategies to Improve Adolescent Retention in HIV Care and Treatment
Adolescents and Young Adults: Mental Health Challenges in Children and Adolescents Living with HIV -
Impact of Mental Health on ART Adherence and HIV Outcomes in Adolescents Living with HIV
Integrating Mental Health Care into Adolescent HIV Care in Low-Resource Settings - Asia/Pacific and Africa
Youth Panel: Discussion Mental Health Issues/Needs by Local Youth
Overview
Welcome
The 15th International Workshop on HIV & Pediatrics took place in a hybrid format from 21-22 July 2023 in the Westin Brisbane Hotel, in Brisbane, Australia.
The International Workshop on HIV & Pediatrics 2024 will take place from 19-20 July 2024 in Munich, Germany.
Although we have witnessed a dramatic global scale-up of antiretroviral treatment (ART) as well as efforts to prevent vertical HIV transmission in the last decade, there were 150,000 new pediatric infections in 2021 and an estimated 1.68 million children <15 years of age living with HIV. Children are substantially less likely than adults to be diagnosed, initiate treatment, and achieve durable viral suppression. Currently, only 54% are receiving ART, and treatment of pediatric HIV, particularly in infants and young children, remains complex and problematic, with continued use of suboptimal ART formulations and regimens.
Furthermore, adolescents are one of the most rapidly growing populations with HIV; in 2021, there were an estimated 410,000 new HIV infections among young people aged 15- 24 years, accounting for 27% of all new HIV infections globally. HIV infections among adolescent girls and young women are 65% higher than among adolescent boys and young men of the same age, with 4,900 new infections occurring in young women weekly. HIV remains one of the leading causes of death among adolescents living in Africa and among the top 10 causes of death in adolescents globally. The uptake of HIV testing among adolescents has remained low. Programs continue to struggle to reach and retain adolescents in care, and adherence to treatment has special challenges, particularly among those with perinatal infection aging up into adolescence and young adulthood.
As research to improve pediatric HIV diagnosis and care is ongoing, new scientific questions of critical importance have also emerged. In settings with mature ART programs, an increasing proportion of new pediatric infections is attributed to women acquiring HIV infection during pregnancy and breastfeeding, periods of markedly increased risk of HIV acquisition for the mother. With the scale-up of ART for PMTCT, the prevalence of pre-treatment antiretroviral (ARV) drug resistance, particularly to non-nucleoside reverse transcriptase inhibitor drugs, has escalated among newly diagnosed infants, jeopardizing ART effectiveness. Additionally, with more than 1.3 million pregnant women globally receiving ART, there are increasing concerns about the long-term impact of in utero and postnatal exposures to medications for those children who escape HIV.
Currently, the global population of HIV-exposed uninfected children and adolescents is estimated at 14.8 million, including over 8 million with in-utero ARV exposure. An initial early report of an association with periconception dolutegravir exposure and increased risk of neural tube defects, which upon an increase in the number of periconception exposures subsequently is no longer found, has underscored the need for ongoing attention to surveillance of safety of ARVs in pregnancy. Innovation in early infant diagnosis such as point-of-care tests has facilitated earlier identification of HIV infection during infancy, providing exciting new opportunities to study acute infection and very early treatment in neonates and promising remission strategies. However, despite the critical importance of these topics, research in pediatric, adolescent, and maternal HIV infection is often neglected at major scientific HIV conferences.
Therefore, in collaboration with leading experts in the field, we have established a highly focused international workshop on the prevention and treatment of pediatric HIV. The overall objective of the International Workshop on HIV & Pediatrics is to stimulate research that will advance prevention and treatment strategies for infants, children, and adolescents.
Local Co-Chairs 2023
Workshop Chairs
General Information
Who Should Attend?
- Researchers
- Clinicians
- Nurses
- Industry specialists working in academic settings, hospitals, and non-governmental organizations (NGO)
- Clinicians
- Nurses
- Industry specialists working in academic settings, hospitals, and non-governmental organizations (NGO)
Meeting Objectives
The meeting aims at:
- Enhancing communication and encouraging collaboration between junior and senior investigators, north and south, and academia, governmental public health agencies, and industry to promote advances in HIV prevention and care in children, adolescents and families.
- Disseminating knowledge and data exchanged by workshop participants beyond the audience of the live event through posting of all presentations on the meeting website, thus maximizing the impact of the meeting by reaching the whole HIV research community.
- Providing updates on the latest research on new pediatric antiretroviral drugs and treatment and prevention strategies in children and adolescents.
- Understanding how to optimize recognition and treatment of advanced HIV disease in children and adolescents.
- Providing updates on new strategies for HIV prevention in children, adolescents and pregnant women, including long-acting antiretroviral agents and HIV vaccines.
- Evaluating effectiveness of and gaps in programs for the prevention of perinatal HIV transmission and interventions to improve such programs.
- Sharing results of implementation science research on how to optimally implement programs for prevention or treatment of HIV in infants, children, adolescents and pregnant women in developing countries.
- Understanding the complications of long-term HIV infection and its therapy, to enable improved management of HIV in children and adolescents.
- Providing update on prevention or treatment of coinfections, such as tuberculosis and hepatitis C, in children and adolescents.
- Enhancing communication and encouraging collaboration between junior and senior investigators, north and south, and academia, governmental public health agencies, and industry to promote advances in HIV prevention and care in children, adolescents and families.
- Disseminating knowledge and data exchanged by workshop participants beyond the audience of the live event through posting of all presentations on the meeting website, thus maximizing the impact of the meeting by reaching the whole HIV research community.
- Providing updates on the latest research on new pediatric antiretroviral drugs and treatment and prevention strategies in children and adolescents.
- Understanding how to optimize recognition and treatment of advanced HIV disease in children and adolescents.
- Providing updates on new strategies for HIV prevention in children, adolescents and pregnant women, including long-acting antiretroviral agents and HIV vaccines.
- Evaluating effectiveness of and gaps in programs for the prevention of perinatal HIV transmission and interventions to improve such programs.
- Sharing results of implementation science research on how to optimally implement programs for prevention or treatment of HIV in infants, children, adolescents and pregnant women in developing countries.
- Understanding the complications of long-term HIV infection and its therapy, to enable improved management of HIV in children and adolescents.
- Providing update on prevention or treatment of coinfections, such as tuberculosis and hepatitis C, in children and adolescents.
Learning Objectives
After attending this meeting, the participants will be able to:
- Describe the changing epidemiology of the pediatric HIV epidemic world-wide and the latest recommendations for pediatric and adolescent HIV treatment.
- Summarize optimal prevention, treatment and management strategies against HIV infection in infants, children, adolescents, as well as in pregnant and postpartum women.
- Describe potential complications of HIV and latest HIV treatments in children, adolescents, and pregnant and postpartum women.
- Summarize approaches to prevent or treat important coinfections in children and adolescents living with HIV.
- Summarize strategies to improve perinatal HIV prevention programs and to better understand continued risk for perinatal transmission in the era of ART.
- Describe special issues related to HIV infection in adolescents and young people, including mental health challenges, as well as new HIV prevention modalities and programming options for the young population.
- Understand new long-acting prevention technologies and their role in the prevention of HIV in adolescents and pregnant women.
- Describe the changing epidemiology of the pediatric HIV epidemic world-wide and the latest recommendations for pediatric and adolescent HIV treatment.
- Summarize optimal prevention, treatment and management strategies against HIV infection in infants, children, adolescents, as well as in pregnant and postpartum women.
- Describe potential complications of HIV and latest HIV treatments in children, adolescents, and pregnant and postpartum women.
- Summarize approaches to prevent or treat important coinfections in children and adolescents living with HIV.
- Summarize strategies to improve perinatal HIV prevention programs and to better understand continued risk for perinatal transmission in the era of ART.
- Describe special issues related to HIV infection in adolescents and young people, including mental health challenges, as well as new HIV prevention modalities and programming options for the young population.
- Understand new long-acting prevention technologies and their role in the prevention of HIV in adolescents and pregnant women.
IAS 2023
HIV & Pediatrics 2023 is an IAS 2023 Affiliated Independent Event.
Practical Information
Venue
HIV & Pediatrics 2023 will take place at the The Westin Brisbane.
Address:
111 Mary St
Brisbane City QLD 4000
Australia
Distance from Brisbane Airport (BNE): 17.6 km
Address:
111 Mary St
Brisbane City QLD 4000
Australia
Distance from Brisbane Airport (BNE): 17.6 km
Entry Requirements
If you are not a citizen of Australia or New Zealand, you are required to apply for a VISA or Electronic Travel Authority (ETA).
To find which type of VISA is applicable to you, please click here: https://immi.homeaffairs.gov.au/visas/getting-a-visa/visa-finder/visit
Important: Please make sure to apply for your VISA at least 3 months before your travel dates.
To find which type of VISA is applicable to you, please click here: https://immi.homeaffairs.gov.au/visas/getting-a-visa/visa-finder/visit
Important: Please make sure to apply for your VISA at least 3 months before your travel dates.
Accommodation
Accommodation is not included in the registration fee.
All registered participants of HIV & Pediatrics 2023 can book a room at the workshop venue at a reduce rate.
Further information will be provided upon completion of registration.
All registered participants of HIV & Pediatrics 2023 can book a room at the workshop venue at a reduce rate.
Further information will be provided upon completion of registration.
Badges
All participants are requested to wear the badge at all times during the workshop to ensure admission to the meeting.
Certificate of Attendance
A certificate of attendance will be sent to participants after they have successfully completed the workshop and post-workshop survey.
Language
The official language of the workshop is English.
Translation will not be provided.
Translation will not be provided.
Enduring Materials
Enduring materials will be available here shortly after the conclusion of the workshop.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the workshop participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Committees
The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.
Scientific Committee
We are proud to present the members of the committee:
-
Marlène Bras, PhD - International AIDS Society, Switzerland
-
Jason Brophy, MD, MSc, DTM, FRCPC - Children's Hospital of Eastern Ontario, Canada
-
Ellen Chadwick, MD - Ann & Robert H. Lurie Children’s Hospital of Chicago / Northwestern University Feinberg School of Medicine, United States
-
Tsungai Chipato, MBChB - University of Zimbabwe College of Health Sciences, Zimbabwe
-
Polly Clayden - HIV i-Base, United Kingdom
-
Anita De Rossi, PhD - University of Padova / Istituto Oncologico Veneto (IOV)-IRCCS, Italy
-
Marinella Della Negra, MD, PhD - Hospital Emilio Ribas, Brazil
-
Brian Eley, MD - University of Cape Town, South Africa
-
Albert Faye, PhD - Denis Diderot University, Paris, France
-
Rashida Ferrand, MBBS, FRCP, PhD - London School of Hygiene and Tropical Medicine / Biomedical Research and Training Institute, Zimbabwe
-
Patricia Flynn, MD - St. Jude Children's Research Hospital, United States
-
Tessa Goetghebuer, MD - Office de la Naissance et de l'Enfance / CHU Saint-Pierree, Belgium
-
Ali Judd, PhD, MRC Clinical Trials Unit, University College London, United Kingdom
-
Valériane Leroy, MD - Inserm, Paris, France
-
Chewe Luo, MD, PhD - UNICEF, United States
-
Dorothy Mbori-Ngacha, MBChB, MMed, MPH - Independent Consultant, Kenya
-
Sharon Nachman, MD - SUNY Stony Brook / IMPAACT, United States
-
Paul Palumbo, MD - Dartmouth-Hitchcock Medical Center, United States
-
Martina Penazzato, MD, MSc, PhD - World Health Organization, Switzerland
-
Natella Rakhmanina, MD, PhD, FAAP, FCP, AAHIVS - Elizabeth Glaser Pediatrics AIDS Foundation / Children’s National Hospital, United States
-
Theodore Ruel, MD - UCSF Benioff Children's Hospital San Francisco, United States
-
George Siberry, MD, MPH, FAAP, FPIDS - United States Agency for International Development (USAID), United States
-
Lynda Stranix-Chibanda, MBChB, MMed - University of Zimbabwe, Zimbabwe
-
Tavitiya Sudjaritruk, MD, ScM, PhD - Chiang Mai University, Thailand
-
Graham Taylor, MD - Imperial College, United Kingdom
-
Claire Thorne, BA, MSc, PhD - University College London, United Kingdom
-
Marissa Vicari, MA - UNAIDS, Switzerland
-
Rachel Vreeman, MD, MS - Icahn School of Medicine at Mount Sinai, United States
The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.
Support
Platinum Level
Silver Level
Bronze Level
Scholarships Supporter
Principal Supporter
Contributor
Award Supporter
Support Our Initiative
Financial backing helps us deliver an impactful meeting experience to the benefit of healthcare professionals and researchers interested in HIV & Pediatrics.
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
To show your commitment to the cause, get in touch with us for a tailored
support package by contacting Ms. Karin Siebelt at Karin.Siebelt@amededu.com.
Benefits of Support
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.
- Symposium opportunities
- Non-commercial interviews with company representatives
- Verbal acknowledgement during the program
- Discounted and complimentary registrations for your representatives
- Company acknowledgement on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
- Company acknowledgement on printed meeting materials including but not limited to banners and the program book
- Digital and printed advertising opportunities
- Social media shout-outs
- Logo on the conference bag
*Subject to the support level.
Downloads:
Endorsers
Endorsers
HIV & Pediatrics 2023 is endorsed by societies and organizations. Their support and collaboration are key to the success of this workshop!
If you would like your organization to endorse the International Workshop on HIV & Pediatrics 2023, please contact Christina Moustakaki at Christina.Moustakaki@amededu.com
Symposium
Ending Pediatric HIV: How Do We Get There?
Program | 22 July 2023 -
Nadia Sam-Agudu, MD, CTropMed
Global Overview on the Status of Early Screening of HIV-Exposed Infants
Challenges and Successes of Implementing Early Screening Program at a Country Level
University of Minnesota / Institute of Human Virology Nigeria, United States / Nigeria
The Role of the Mentor Mothers Programs in The Implementation of Early Infant Testing
ViiV Healthcare
This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Photo Gallery
Group Photo
Media
15th Anniversary of the International Workshop on HIV & Pediatrics
HIV & Pediatrics 2023 - Highlights Video
Previous Editions
Previous Editions
- 14th Edition - International Workshop on HIV Pediatrics, 2022, Canada
- 13th Edition - International Workshop on HIV Pediatrics, 2021, Virtual
- 12th Edition - International Workshop on HIV Pediatrics, 2020, Virtual
- 11th Edition - International Workshop on HIV Pediatrics, 2019, United States
- 10th Edition - International Workshop on HIV Pediatrics, 2018, The Netherlands
- 9th Edition - International Workshop on HIV Pediatrics, 2017, France
- 8th Edition - International Workshop on HIV Pediatrics, 2016, South Africa
- 7th Edition - International Workshop on HIV Pediatrics, 2015, Canada
Language
Related Programs
